aTyr Pharma, Inc. (LIFE): Price and Financial Metrics
LIFE Price/Volume Stats
| Current price | $1.60 | 52-week high | $2.70 |
| Prev. close | $1.60 | 52-week low | $1.08 |
| Day low | $1.54 | Volume | 306,500 |
| Day high | $1.62 | Avg. volume | 503,026 |
| 50-day MA | $1.81 | Dividend yield | N/A |
| 200-day MA | $1.62 | Market Cap | 108.37M |
LIFE Stock Price Chart Interactive Chart >
aTyr Pharma, Inc. (LIFE) Company Bio
aTyr Pharma, Inc. is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. aTyr research and development focuses on the extracellular functionality and signaling pathways of tRNA synthetases. Over the last ten years, the company has developed an international portfolio of intellectual property, including 20 human tRNA synthetases and over 300 protein compositions patented. Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. aTyr’s headquarters is located in San Diego, California and the company employs 42 people.
Latest LIFE News From Around the Web
Below are the latest news stories about ATYR PHARMA INC that investors may wish to consider to help them evaluate LIFE as an investment opportunity.
aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With LossesInsiders who bought US$501.6k worth of aTyr Pharma, Inc.'s ( NASDAQ:LIFE ) stock at an average buy price of US$2.23... |
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology (ACR) Convergence 2 |
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate UpdatePhase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated patient dosing. Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of firs |
aTyr Pharma to Present at November Investor ConferencesSAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences scheduled to take place in November 2023. Details of the presentations appear below: Conference: Jefferies London Healthcare C |
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILDMultiple centers in the U.S. are open for enrollmentSAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has dosed the first patient in its Phase 2 EFZO-CONNECT™ study. The proof-of-concept study will evaluate the efficacy, safety and tolerability of the Company’s lead the |
LIFE Price Returns
| 1-mo | -20.00% |
| 3-mo | 1.27% |
| 6-mo | 33.33% |
| 1-year | -19.60% |
| 3-year | -60.59% |
| 5-year | -83.19% |
| YTD | 13.48% |
| 2023 | -35.62% |
| 2022 | -70.68% |
| 2021 | 92.53% |
| 2020 | -6.95% |
| 2019 | -39.95% |
Continue Researching LIFE
Want to see what other sources are saying about aTYR PHARMA INC's financials and stock price? Try the links below:aTYR PHARMA INC (LIFE) Stock Price | Nasdaq
aTYR PHARMA INC (LIFE) Stock Quote, History and News - Yahoo Finance
aTYR PHARMA INC (LIFE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...